{
    "clinical_study": {
        "@rank": "68751", 
        "arm_group": [
            {
                "arm_group_label": "Cenicriviroc + Midazolam, and CVC + DTG", 
                "arm_group_type": "Experimental", 
                "description": "Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 & w/ CVC 150mg on Day 9."
            }, 
            {
                "arm_group_label": "Dolutegravir , and DTG + CVC", 
                "arm_group_type": "Experimental", 
                "description": "Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and\n      without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy\n      subjects."
        }, 
        "brief_title": "Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "HIV-infection/AIDS", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Objectives\n\n        -  To evaluate the steady-state PK of CVC administered with and without DTG .\n\n        -  To evaluate the steady-state PK of DTG administered with and without CVC .\n\n        -  To evaluate the PK of a single dose of Midazolam administered with and without steady\n           state CVC when both are administered orally.\n\n      Secondary Objectives\n\n        -  To evaluate the safety and tolerability of CVC administered with and without DTG.\n\n        -  To evaluate the safety and tolerability of CVC administered with and without Midazolam."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Provide written informed voluntary consent\n\n          2. Adult male and female healthy volunteers\n\n          3. Body mass index (BMI) \u2265 18.0 and \u2264 30.0 kg/m2.\n\n          4. Be in good general health with no clinically relevant abnormalities\n\n          5. Agree to comply with study procedures and restrictions\n\n        Exclusion Criteria:\n\n          1. Any disease or condition that might affect drug absorption, metabolism, or excretion,\n             or clinically significant cardiovascular as determined by investigator\n\n          2. History of stomach or intestinal surgery, except for fully healed appendectomy and/or\n             cholecystectomy which will be allowed\n\n          3. Clinically significant illness or clinically significant surgery within 4 weeks\n             before the administration of study medication\n\n          4. Known or suspected hypersensitivity or allergic reaction to any of the components of\n             CVC or DTG tablets, or midazolam syrup\n\n          5. Serum ALT, AST, or bilirubin values greater than or equal to Division of Acquired\n             Immunodeficiency Syndrome (DAIDS) grade 1 at screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827540", 
            "org_study_id": "TBR 652-1-110"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cenicriviroc + Midazolam, and CVC + DTG", 
                    "Dolutegravir , and DTG + CVC"
                ], 
                "intervention_name": "Cenicriviroc", 
                "intervention_type": "Drug", 
                "other_name": "CVC"
            }, 
            {
                "arm_group_label": [
                    "Cenicriviroc + Midazolam, and CVC + DTG", 
                    "Dolutegravir , and DTG + CVC"
                ], 
                "intervention_name": "Dolutegravir", 
                "intervention_type": "Drug", 
                "other_name": "DTG"
            }, 
            {
                "arm_group_label": "Cenicriviroc + Midazolam, and CVC + DTG", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Dormicum", 
                    "Hypnovel", 
                    "Versed"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "HIV/AIDS", 
            "Cenicriviroc (CVC)", 
            "Dolutegravir (DTG)", 
            "Midazolam", 
            "Healthy Subjects"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33126"
                }, 
                "name": "SeaView Research, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Multiple-Dose, Open-Label, Crossover Study in Healthy Subjects to Assess the Effect of Dolutegravir (DTG) on the Pharmacokinetics (PK) of Cenicriviroc (CVC) and the Effect of CVC on the PK of DTG and on a Single Dose of Midazolam", 
        "overall_official": {
            "affiliation": "SeaView Research, Inc.", 
            "last_name": "Audrey Martinez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "PK profile will be calculated based on CVC exposure. Trough (predose) CVC plasma samples will be obtained prior to dosing on Days 2-9 & 12-19.", 
                "measure": "Pharmacokinetic Assessment of Cenicriviroc", 
                "safety_issue": "No", 
                "time_frame": "0 (predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, & 24 hours postdose on Days 10 and 20"
            }, 
            {
                "description": "PK profile will be calculated based on DTG exposure. Trough (predose) DTG plasma samples will be obtained prior to dosing on Days 2-9 & 12-19.", 
                "measure": "Pharmacokinetic Assessment of Dolutegravir", 
                "safety_issue": "No", 
                "time_frame": "0 (predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, & 24 hours postdose on Days 10 and 20"
            }, 
            {
                "description": "PK profile will be calculated (Group 1 only) based on plasma midazolam & alpha-hydroxymidazolam exposure.", 
                "measure": "Pharmacokinetic Assessment of Midazolam and alpha-hydroxymidazolam", 
                "safety_issue": "No", 
                "time_frame": "0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 & 18 hours postdose on Day -1 and Day 9"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Physical examinations, vital signs, ECGs, clinical laboratory tests, and AEs or serious AEs (SAEs) will be assessed at specified time points according to the Schedule of Procedures in the protocol. In addition, arterial oxygen saturation will be monitored by pulse oximetry for at least 2 hours after administration of midazolam on Days -1 and 9 in Group 1.\nFor both groups, a final follow-up visit will occur 14 days (\u00b13 days) after the last dose of study medication, or at the time of early termination (if applicable) to evaluate any remaining safety issue(s).", 
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed upon taking first dose of study medication until the follow-up visit, an expected average of 5 weeks"
        }, 
        "source": "Tobira Therapeutics, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "ViiV Healthcare", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Tobira Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}